Eikon Therapeutics’ Post

🚀 Exciting Announcement at JPM Healthcare Conference! 🌐 We are thrilled to share that at the JPM Healthcare Conference on January 9th, Dong-A ST and Eleven Therapeutics inked a Memorandum of Understanding (MoU). Under this MOU, the companies will focus on developing RNA-based therapies for fibrotic diseases using Eleven’s high throughput screening platform, TERÅ®, which is used to find the most suitable non-canonical elements in therapeutic xRNA molecules. We are excited to put together this collaboration with Dong-A ST and expand our R&D efforts to tackle unmet medical needs in fibrotic disorders. Dong-A ST’s team brings a wealth of experience in this therapeutic area, complementing Eleven’s prowess in next generation mRNAs. This partnership can allow us to expand into new markets, and adds to our growing set of collaborations, ultimately aimed to accelerate the translation of our groundbreaking xRNA modality into a solution for a multitude of devastating ailments. Read more: https://shorturl.at/cpERV #11TX #HealthcareInnovation #GeneTherapy #Biotechnology #Partnership #MedicalResearch #JPMHealthcareConference #FibrosisTreatment 💊

Global collaborations with Pharmaceutical leaders serve to amplify our own pipeline and fulfill Eleven Therapeutics' mission to translate our xRNA modality into impactful medicines. The MOU signed last week with Dong-A ST (see below), under the championship of Jaehong Park, president and CSO, is a springboard to exploring the ways that xRNA, empowered by TERA, can accelerate R&D of #FibroticDisorder medicines. What a great way to kick start 2024!

What challenges does the advanced therapies sector face? Over the three days of Advanced Therapies Week (ATW) 2024 in Miami, Florida, US, 16-19 January 2024, DDW’s Megan Thomas heard from attendees about the obstacles the sector needs to overcome to succeed. https://lnkd.in/dev8gwmq #AdvancedTherapies #AdvancedTherapiesWeek #LifeSciences

In search of advanced or metastatic non-clear cell renal cell carcinoma clinical trial options for your patients living with cancer? Try searching for trials via CancerCare's myTRIAList trial finder and explore clinical trial options that might be right for you, such as the STELLAR-304 study. https://buff.ly/3thMHTv #clinicaltrials #pharmaceutical #biotechnology #science #research #solutions

Come join Shaheen E Lakhan, MD, PhD, FAAN and I tomorrow at the Future Health: Best Practices for Advancing Care conference. We are excited to be invited back again this year to share all about the latest advances in prescription digital therapeutics with such a prestigious group! #healthcare #digitalmedicine #digitaltherapeutics #AI

🔬 Exciting findings from the ENVISION trial: UBX1325 shows promise in advanced #wetAMD cases. Despite not meeting primary endpoint, it's safe and well-tolerated. Dr. raj maturi shares insights on its unique mechanism targeting senescent cells. Significant proportion of patients didn't require anti-VEGF treatment through 24 weeks. Secondary analysis hints at efficacy in longer disease duration patients. Ongoing exploration of combination therapy potential in Part B of ENVISION study. 👉 Learn more in this article from Healio by Michela Cimberle, fact checked by Christine Klimanskis #agerelatedmaculardegeneration #maculardegeneration #cataract #ophthalmology #ophthalmologynews

Join Dr. Young Wang, MD, and Dr. Ingela Mauritzon, PhD, on Wednesday, February 14 at 12:00 PM ET, as they guide you through the intricacies of in vitro diagnostics (IVD). This live webinar addresses the pressing need for standardized regulatory practices in the field of IVDs as advancements are made in an increasingly interconnected global healthcare landscape and demand grows for more precise diagnostics. Enroll today (with or without contact hours) > https://bit.ly/3RV3Sm5 #ACRP #Webinar #ContinuingEducation #InVitroDiagnostics #IVD

Congrats to our clinical data manager Sara Anderson (Weigel) who spoke at the 2024 Zelta User Conference hosted by Merative in Boston earlier this month. Sara shared her perspective on how SPR Therapeutics leverages Zelta for post-market, retrospective real-world data collection.    Zelta is a large part of our clinical study process. We use their clinical data management platform to build and house the databases for our clinical trials. When our study sites enter subject data into the system, it provides our clinical and R&D teams with the ability to monitor, compile and analyze the data. The data is then used to develop abstracts, journal articles and symposium presentations. It is a tool that allows us to be true partners with all of our clinical study sites and offer real-world perspectives in data to educate others about peripheral nerve stimulation.   #PNS #SprintPNS #neuromodulation #clinicaltrials #clinicaldata #clinicalstudies #professionaleducation #leadersinmeddevice #meddeviceleaders

Newsweek's 'The New Era of Life Sciences 2024' report spoke to prominent Life Science thought leaders including ChromaDex CEO, Rob Fried, about the current state of the industry. The report highlights ChromaDex's work on addressing #healthyaging through our focus on #NAD+ and Niagen #nicotinamideriboside (NR), and shares our commitment to rigorous scientific research, regulatory compliance, and safety in the supplement industry. https://bit.ly/3UK5eBc

Exciting updates from Bristol Myers Squibb on #mezigdomide (#CC92480) in combination with tazemetostat and dexamethasone for multiple myeloma! #Mezigdomide, a potent #CELMoD under investigation, has shown promising preclinical results, being significantly more potent than #iberdomide and other #IMiDs. In the CA057-003 trial (#NCT05372354), 13 patients who had undergone a median of 5 prior lines of therapy received #mezigdomide, #tazemetostat, and #dexamethasone. The overall response rate (ORR) was 53.8%, with higher mezigdomide doses yielding an ORR of 71.4%. The combination demonstrated a manageable safety profile, with grade 3/4 TEAEs occurring in 69.2% of patients. Notably, mezigdomide rapidly degrades Ikaros and Aiolos proteins, inducing apoptosis in multiple myeloma cells and stimulating the immune system. The future of CELMoDs like mezigdomide looks promising as they continue to show high synergy with traditional partners and advanced treatments. Get detailed analysis of the abstract here @ https://lnkd.in/eq2-MY47 Stay tuned for more updates! #MultipleMyeloma #ClinicalTrials #Mezigdomide #BMS #CancerResearch #CELMoDs #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #myeloma #oncology #pharmacautical #hematology